Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

Inclusion criteria

• Regularly taking any moderate-intensity or higher dose* of statin stabilization therapy for ≥4 weeks at screening:

• ASCVD risk is ultra-high risk Fasting LDL-C ≥ 1.4 mmol/L;
• ASCVD risk very high risk Fasting LDL-C ≥1.8 mmol/L;
• ASCVD risk is intermediate or high risk Fasting LDL-C ≥ 2.6 mmol/L.
• Any other condition that is not met at screening Regularly taking any moderate intensity and higher dose* statin stabilization therapy for ≥4 weeks;

a) Fasting LDL-C ≥ 2.6 mmol/L.

• Fasting triglycerides ≤ 5.6 mmol/L.

Exclusion criteria

• Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes at screening (HbA1c > 8.5%).
• eGFR <30ml/min/1.73m2 at the screening visit.
• CK >5times ULN at the screening visit.